Drug intelligence / Profile preview

Betula lenta pollen extract

Development stage
Unknown
Lead developer
ALK Abelló
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Intradermal, Subcutaneous, Percutaneous
01

Overview

Betula lenta pollen extract is an allergenic extract derived from the pollen of the Betula lenta (black or cherry birch) tree. It is used for both the diagnosis (via skin testing) and treatment (via immunotherapy) of allergies to birch pollen. [19, 23] As a non-standardized biological extract, it contains various allergenic proteins from the pollen. [23] Administration is typically through injection (subcutaneous, intradermal, or percutaneous). The principle of immunotherapy involves administering gradually increasing doses of the allergen to modulate the immune system's response, leading to increased tolerance and a reduction in allergic symptoms upon environmental exposure. [4, 9] The product is marketed by companies such as ALK-Abello, Inc. and Allermed Laboratories, Inc.

Other names
Betula lenta pollenSweet Birch pollen extractCherry Birch pollen extract
02

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on Betula lenta pollen extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Betula lenta pollen extract.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call